Cambridge Healthtech Institute’s 13th Annual

GLP1 & Oral Peptides

Obesity-Related Drug Discovery Advances

April 15 - 16, 2025 ALL TIMES PDT

The promise of anti-obesity therapeutics is generating a flurry of related research and drug development in the pharmaceutical and medical research establishment. In 2021, the FDA approved the first chronic weight-loss-specific medication, Wegovy, based on agonists of the glucagon-like peptide (GLP) receptor; GLP1 agonists were originally launched for diabetes. At CHI’s GLP1 & Oral Peptides conference, leading discovery chemists will convene to share progress and innovations spurred by GLP1R agonist-focused drug development, including the development of oral peptides. We also cover obesity-related therapeutic progress beyond GLP1 peptides such as the development of small molecules and 2nd generation compounds.